Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced that it will present new data on its drug FILSPARI® (sparsentan) at the 15th International Podocyte Conference in Hamburg, Germany, scheduled for June 10-13, 2025. The company will showcase three abstracts detailing the drug's effects in rare kidney diseases. New findings from the Phase 2 SPARTAN Study indicate that FILSPARI demonstrates antifibrotic and anti-inflammatory properties, impacting B cell and complement pathways in IgA nephropathy (IgAN). The data reveals rapid and sustained reductions in urinary biomarkers associated with disease progression, suggesting potential disease-modifying effects. The presentations will take place on Friday, June 13, 2025, at the Kleiner Festsaal and Small Banquet Hall, covering various aspects of FILSPARI's efficacy in treating kidney-related conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.